Contact this trialFirst, we need to learn more about you.
Cell Cycle Inhibitor
Onvansertib + Paclitaxel for Breast Cancer
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial is testing the safety and effectiveness of combining Onvansertib, an experimental drug, with Paclitaxel, a chemotherapy drug, in patients with advanced triple-negative breast cancer. The goal is to find the best dose of Onvansertib and see if this combination can help treat this aggressive form of cancer.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service